{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:46:24Z","timestamp":1790027184196,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T00:00:00Z","timestamp":1206662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The authors previously developed a melanoma\u2010specific module for the Functional Assessment of Cancer Therapy (FACT\u2010Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT\u2010Melanoma was examined in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients with melanoma (N = 273; stages I\u2010IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT\u2010Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe\u2010Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test\u2010retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>The internal consistency and test\u2010retest reliability (r) of the melanoma subscale (Cronbach \u03b1 = .85; r = .81) and the total FACT\u2010Melanoma (\u03b1 = .95; r = .90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT\u2010Melanoma scores, along with scores for physical well\u2010being, emotional well\u2010being, functional well\u2010being, and melanoma\u2010specific scales, were lower for patients with advanced (stage III\/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT\u2010Melanoma total score and the score for physical well\u2010being were sensitive to changes in performance status (<jats:italic>P<\/jats:italic> = .0012 and <jats:italic>P<\/jats:italic> = .004, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The results of the current study indicated that the FACT\u2010Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23424","type":"journal-article","created":{"date-parts":[[2008,3,29]],"date-time":"2008-03-29T01:40:22Z","timestamp":1206754822000},"page":"2249-2257","source":"Crossref","is-referenced-by-count":84,"title":["Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy\u2010Melanoma questionnaire"],"prefix":"10.1002","volume":"112","author":[{"given":"Janice N.","family":"Cormier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick I.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Lynn","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90115-V"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2256"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00333-Z"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg010"},{"key":"e_1_2_6_6_2","first-page":"164","article-title":"Fatigue in patients with cancer receiving interferon alpha","volume":"3","author":"Dean GE","year":"1995","journal-title":"Cancer Pract."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200209000-00013"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008995814965"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1611(200007\/08)9:4<283::AID-PON460>3.0.CO;2-N"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000012266"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198301000-00016"},{"key":"e_1_2_6_12_2","first-page":"353","article-title":"Perceived well\u2010being in malignant melanoma survivors","volume":"16","author":"Dirksen SR","year":"1989","journal-title":"Oncol Nurs Forum."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.2960010204"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71241-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(97)71503-2"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2844"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-199201000-00007"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(82)70155-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-8343(94)00098-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-198712000-00006"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-199512000-00002"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1990.01810200028004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11579"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/10547730022158537"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869609098495"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/clon.2001.9314"},{"key":"e_1_2_6_27_2","first-page":"133","article-title":"Interferon\u2010alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi\u2010institutional Australian randomized trial","volume":"3","author":"Thomson DB","year":"1993","journal-title":"Melanoma Res."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00372-1"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2001.01755.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435223"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.974"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-5002(95)00450-F"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008821826499"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","unstructured":"CormierJN DavidsonLN WebsterKA CellaD.Development of a melanoma\u2010specific subscale for the Functional Assessment of Cancer Therapy (FACT\u2010Melanoma) [abstract]. 2004 ASCO Annual Meeting Proceedings (Post\u2010Meeting Edition). J Clin Oncol.2004; 22 (14S). Abstract 8122.","DOI":"10.1200\/jco.2004.22.90140.8122"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.7s102.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422214"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2002.36959"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909309024860"},{"key":"e_1_2_6_41_2","first-page":"139","article-title":"Measuring quality of life in patients with melanoma: development of the FACT\u2010Melanoma subscale","volume":"3","author":"Cormier JN","year":"2005","journal-title":"J Support Oncol."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90143-3"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0047358"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(60)90137-5"},{"key":"e_1_2_6_45_2","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky DA","year":"1949"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/med:psych\/9780195126709.001.0001"},{"key":"e_1_2_6_48_2","volume-title":"Practical Nonparametric Statistics","author":"Conover WJ","year":"1999"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1907"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23424","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:05:54Z","timestamp":1760292354000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,28]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,5,15]]}},"alternative-id":["10.1002\/cncr.23424"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23424","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,28]]}}}